Ipilimumab +Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Soft Tissue Sarcoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Primary Objectives: 1) Assess whether the rate of clinical benefit is sufficiently high to merit promise for further study Secondary Objectives: Characterize the 6-month progression-free survival rate Assess whether the treatment yields a reasonably safe and tolerable profile
Primary Objectives: 1) Assess whether the rate of clinical benefit is sufficiently high to merit promise for further study Secondary Objectives: Characterize the 6-month progression-free survival rate Assess whether the treatment yields a reasonably safe and tolerable profile
Tracking Information
- NCT #
- NCT04118166
- Collaborators
- Bristol-Myers Squibb
- Investigators
- Principal Investigator: Kristen Ganjoo, MD Stanford University
Get Well Soon